Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073476 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00073476 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 300 participants.
The verdict
NCT00073476, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Interventions
- DRUG traxiprodil (CP-101,606)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073476
The ClinicalTrials.gov registry entry for NCT00073476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which traxiprodil (CP-101,606) is the first listed.
NCT00073476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073476 about?
NCT00073476 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke". The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
What is the current status of trial NCT00073476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2003-09. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00073476?
The interventions under investigation include: traxiprodil (CP-101,606) (DRUG).
Who is sponsoring clinical trial NCT00073476?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.